MannKind partners with Rose Pharma to develop inhaled GLP-1 treatment
MannKind (MNKD) is partnering with Rose Pharma to develop an inhaled weight-loss treatment using MannKind’s Technosphere platform, targeting the GLP-1 weight-loss market.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.